Abstract
Over 11,000 people in the US are diagnosed with acute myeloid leukemia (AML) each year, and despite attempts to improve therapy, the overall 5-year survival remains 26%, largely due to a high rate of relapse. Defining the mechanisms responsible for persistence of the malignant clone is essential to
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
